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Background: Metabolic complications are associated with clinical outcomes in patients with chronic kidney disease
(CKD). These outcomes differ among patients according to the different stages of disease. The prevalence and
association of type and number of metabolic complications with renal progression and death in patients having
different eGFR levels has high clinical value, but this fact has been rarely evaluated in prospective studies.
Methods: We prospectively followed a cohort of 1157 CKD patients from 2006 to death or until 2010, and
evaluated the prevalence of CKD-related complications and their association with renal progression (defined as a
decline in eGFR by > 50% from baseline, or end-stage renal disease requiring dialysis) and death in patients with
eGFRs above and below 45 mL/min/1.73 m2 using Cox-proportional hazard models.
Results: The estimated rate (per 100 patient-years) of renal progression and death were 11.9 and 4.9, respectively.
The eGFR thresholds determined by ROC analysis with a sensitivity of 90% for any metabolic complication were
60.8 mL/min/1.73 m2 and 74.3 mL/min/1.73 m2 using the MDRD and CKD Epidemiology Collaboration equations,
respectively. CKD-related complications associated with renal progression in patients having eGFR < 45 mL/min/1.73m2
were hyperphosphatemia, anemia, microinflammation and hypoalbuminemia. Those CKD-related complications
associated with death were hypoalbuminemia and hyperuricemia. Hypoalbuminemia predicted renal progression, and,
hypoalbuminemia and microinflammation predicted death in patients with eGFR≥ 45 mL/min/1.73m2. The number of
complications (≥ 3) independently predicted both endpoints in patients with eGFR < 45 mL/min/1.73m2.
Conclusions: Hypoalbuminemia was a unique and strong predictor of renal progression and all-cause mortality in CKD
patients, independent of their demographic characteristics, traditional risk factors, renal function severity, the presence of
cardiovascular disease and other metabolic abnormalities. Most other metabolic complications and the number of
complications (≥3) were associated with the clinical outcomes of patients with eGFR < 45 mL/min/1.73m2 rather than in
those with higher eGFRs. The findings from the present study offer a novel insight into the association between
metabolic complications and patient outcomes and may help to refine risk stratification according to disease stage.
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The metabolic complications are associated with clinical
outcomes in patients with chronic kidney disease (CKD).
Patients with stage 3 CKD are more likely to die than
undergo renal progression. In contrast, patients with
stages 4 and 5 CKD who survive this life-threatening
condition, are at greater risk of end-stage renal disease
(ESRD) than death [1,2]. Numerous CKD-related meta-
bolic complications develop undetected and asymptom-
atically at disease onset, before progression to renal
failure and death. The associations renal progression and
death with traditional risk factors and selected complica-
tions, such as anemia [3], calcium-phosphate imbalance
[4], hyperkalemia [5], acidosis [6], hyperuricemia [7] and
malnutrition–inflammation [8] have been extensively
studied in patients with CKD. However, whether the
type and number of CKD-related complications have
similar impacts on clinical outcomes in patients with dif-
ferent estimated glomerular filtration rates (eGFRs) re-
mains unclear.
The NKF/DOQI classification of CKD encompasses a
wide range of patients within stage 3. The high estimates
of the prevalence of this disease may partially represent
an over diagnosis of kidney dysfunction due to misclassi-
fication of asymptomatic patients as having “pre-disease”
or a “high-risk” condition when abnormal laboratory re-
sults arise. This may cause unnecessary concern among
patients leading to the potential overuse of subspecialty
resources. For this reason, a Report of KDIGO Contro-
versies Conference proposed the subdivision of stage 3
into “3a” and “3b” strata at an eGFR of 45 mL/min/1.73 m2
[9]. Elucidating the relationship among different meta-
bolic complications with clinical outcomes in patients
with eGFRs above and below 45 mL/min/1.73 m2 would
be valuable. Given the high disease burden and the revers-
ible nature of stage 3 CKD improving our knowledge of
the factors associated with renal progression and death in
patients with eGFRs above and below 45 mL/min/1.73 m2
is essential.
We conducted a prospective cohort study to (1) inves-
tigate the prevalence of CKD-related metabolic compli-
cations in patients with eGFR above and below 45 mL/
min/1.73 m2, and, (2) evaluate the predictive role of these
abnormalities on renal progression (defined as a decline
in eGFR by >50% from baseline, or ESRD requiring
dialysis) and all-cause death based on this eGFR cut-off.
Methods
Patient selection and study design
All participants were predialysis CKD patients who partici-
pated in the Multidisciplinary Predialysis Education pro-
gram [10] at outpatient clinics held at the Department of
Nephrology of Chang Gung Memorial Hospital at Keelung
from May. Patients were followed up until April 15, 2010,or until they died, or were lost from the study. A total of
1157 patients aged 18–90 years without renal graft failure,
or spontaneous improvement or progression of renal dis-
ease in the previous 3 months were enrolled in this study
after informed consents were obtained. CKD was defined
as having persistent proteinuria or a decreased eGFR of
less than 60 mL/min/1.73 m2, determined by the abbrevi-
ated Modification of Diet in Renal Disease (MDRD)
equation in 2 separate measurements within an interval
of 3 months. Serum Cr was assessed by spectrophotomet-
ric analysis using a modified kinetic Jaffe reaction with
standardization of the creatinine calibration to an isotope
dilution mass spectrometry (IDMS) reference measure-
ment procedure. This study was conducted in adherence
with the Declaration of Helsinki and was approved by the
Ethics Committee of the Institutional Review Board at the
Chang Gung Memorial Hospital.
Definitions
All clinical data and biological parameters were collected
at baseline upon entry into the study. We defined CKD-
related complications as follows: anemia, hemoglobin levels
less than 13.5 g/dL in men or 12 g/dL in women [11] or
the use of erythropoiesis-stimulating agents; hyperkalemia,
K greater than 5 mEq/L or ion-exchange resin therapy;
acidosis, CO2 less than 22 mmol/L or bicarbonate treat-
ment; hypocalcemia, corrected Ca less than 8.5 mg/dL;
hyperphosphatemia, P greater than 4.5 mg/dL or phos-
phate binder use; hyperparathyroidism, intact parathyroid
hormone more than twice the upper limit of normal,
corresponding to 70 pg/mL [12]; hyperuricemia, uric
acid levels more than 8.0 mg/dL, or treatment with
hypouricemic agents; and, hypoalbuminemia, serum albu-
min concentration less than 3.6 mg/dL. Obesity was evalu-
ated according to the WHO classification as having a body
mass index (BMI) of 30 kg/m2 or more. Renal function
was checked during follow-up visits and at regular intervals
according to the NKF/DOQI recommendations (stage 1
and 2 CKD patients were followed-up every 6 months;
stage 3 or 4 CKD, every 3 months and stage 5 CKD pa-
tients, on a monthly basis). Renal progression was defined
as a decline in eGFR by >50% from baseline or ESRD
requiring dialysis. Mortality was carefully revised from
the medical records. Patients or their relatives were
telephoned when patients were lost to follow-up for lon-
ger than 3 months. Cases lost to follow-up in the subse-
quent visits were censored in the analysis. Deaths that
occurred outside the hospital were verified by relatives
during the telephone calls.
Statistical methods
Descriptive statistics were expressed as the mean ±
standard deviation, median (range), and/or frequency
(percentage) where appropriate. All numerical variables
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Smirnov test. Data were log-transformed to approxi-
mate a normal distribution with right skewness. The
Student’s t test or Mann–Whitney U test was appliedTable 1 Demographic characteristics stratified by CKD stages
Stage 1 Stage 2
(n = 44) (n = 102)
Age, years 55.6 ± 13.5* 59.5 ± 14.1*
Male, No. (%) 11 (25%) 57 (55.9%)
Diabetes, No. (%) 17 (38.6%) 25 (24.5%)
Hypertension, No. (%) 23 (52.3%) 44 (43.1%)
Primary cause
Diabetes, No. (%) 16 (36.4%) 18 (17.8%)
Hypertension, No. (%) 4 (9.1%) 14 (13.9%)
CGN, No. (%) 3 (6.8%) 4 (4%)
Gout, No. (%) 2 (4.5%) 21 (20.8%)
Obstructive uropathy, No. (%) 0 (0%) 0 (0%)
ADPKD, No. (%) 1 (2.3%) 1 (1%)
Unknown/other, No. (%) 18 (40.9%) 43 (42.6%)
Body mass index, kg/m2 27.1 ± 5.9* 25.5 ± 3.6*
Systolic BP, mmHg 131 ± 18 131 ± 17
Diastolic BP, mmHg 75 ± 9 75 ± 9
Laboratory
eGFR, mL/min per 1.73 m2 (MDRD) 112.8 ± 30.8* 72.6 ± 8.4*
eGFR, ml/min per 1.73 m2 (EPI) 115.2 ± 32.4* 76.8 ± 10.2*
eGFR, mL/min per 1.73 m2 (CG) 119 ± 35.8* 81.2 ± 18.7*
BUN, mg/dL 14 ± 5* 15 ± 5*
Serum creatinine, mg/dL 0.6 ± 0.1* 0.9 ± 0.1*
Hemoglobin, g/dL 13.7 ± 1.6* 14.1 ± 1.7*
Serum sodium, mEq/L 140 ± 2.4 141 ± 2.1
Serum potassium, mEq/L 4.1 ± 0.4* 4.2 ± 0.6*
Serum calcium, mg/dL 9.3 ± 0.4 9.3 ± 0.3
Serum phosphate, mg/dL 4.1 ± 1 4.4 ± 0.9
Serum chloride, mEq/L 104 ± 3 103 ± 9
Serum bicarbonate, mmol/L 26.6 ± 2.1* 27.2 ± 2.9*
Serum uric acid, mg/dL 4.8 ± 1.4* 4.9 ± 1.6*
Serum albumin, g/dL 4.2 ± 0.4* 4.2 ± 0.3*
Cholesterol, mg/dL 213 ± 53* 206 ± 41*
iPTH, pmol/L 43.2 (13.1, 87.3)* 48.4 (13.8, 135)*
hs-CRP, mg/L 1.5 (0.2, 21.3)* 1.0 (0.2, 56.4)*
Microalbuminuria, mg/day 225 ± 46* 291 ± 25*
Cardiovascular disease, No. (%) 2 (4.5%) 6 (5.9%)
Use of ACEI/ARB, No. (%) 3 (6.8%) 6 (5.9%)
The values are expressed as means (SD) or median (Min, Max). CGN, chronic glome
polycystic disease; BP; blood pressure; eGFR, estimated glomerular filtration rate; M
Collaboration; CG, Cockcroft-Gault; BUN; blood urea nitrogen; iPTH, intact parathyro
ACEI, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; *p < 0.05to compare continuous variables between groups. Cat-
egorical data were analyzed using the chi-squared test.
Cumulative renal survival and patient survival were es-
timated using the Kaplan–Meier method. Adjusted risk(n = 1157)
Stage 3a Stage 3b Stage 4 Stage 5
(n =96) (n = 195) (n = 389) (n = 331)
65.8 ± 13.8* 68.2 ± 12.9* 69.3 ± 12.8* 67.4 ± 12.3
68 (70.8%) 135 (69.2%) 216 (55.5%) 156 (47.1%)
27 (28.1%) 86 (44.1%) 212 (54.6%) 193 (58.3%)
66 (68.8%) 149 (76.4%) 312 (80.4%) 272 (82.2%)
29 (29.2%) 77 (39.6%) 193 (49.6%) 175 (52.9%)
14 (14.6%) 12 (6%) 27 (6.9%) 8 (2.4%)
2 (2.2%) 17 (8.8%) 46 (11.7%) 64 (19.2%)
23 (22.5%) 37 (18.7%) 48 (12.3%) 17 (5.1%)
0 (0%) 3 (1.6%) 5 (1.4%) 12 (3.7%)
0 (0%) 5 (2.7%) 7 (1.7%) 3 (1%)
30 (31.5%) 43 (22.5%) 63 (16.3%) 52 (15.8%)
26.0 ± 4.8* 25.7 ± 3.6* 25.8 ± 4.1 * 24.8 ± 4.0
135 ± 16 134 ± 18 137 ± 20 140 ± 21
77 ± 10 73 ± 11 71 ± 11 72 ± 10
51.8 ± 4.2* 36.2 ± 3.8* 22.1 ± 4.1* 9.4 ± 3.2
62.5 ± 11.9* 41.7 ± 8.5* 23.4 ± 6.9* 9.7 ± 4.0
65.5 ± 41.3* 26.7 ± 8.7* 12.3 ± 4.3* 12.2 ± 4.3*
19 ± 7* 25 ± 10* 28 ± 15* 67 ± 29
1.1 ± 0.1* 1.5 ± 0.1* 2.4 ± 0.4* 5.5 ± 2.2
13.9 ± 1.9* 12.7 ± 2.1* 11.3 ± 2.0* 9.6 ± 1.6
141 ± 2.6 139 ± 3.4 138 ± 7.7 137 ± 10
4.4 ± 0.5* 4.3 ± 0.6* 4.5 ± 0.6* 4.7 ± 0.8
9.4 ± 0.5 9.3 ± 0.5 9.2 ± 0.6 8.6 ± 0.7
4.4 ± 1.6 4.7 ± 1.7 4.7 ± 1.7 4.9 ± 1.3
104 ± 3 104 ± 9 105 ± 8 103 ± 17
27.5 ± 2.4* 26.4 ± 2.9* 24.6 ± 3.4* 20.8 ± 4.5
5.5 ± 2.4* 6.7 ± 2.3* 7.7 ± 2.0* 7.8 ± 1.9
4.1 ± 0.4* 3.9 ± 0.6* 3.7 ± 0.6* 3.5 ± 0.6
199 ± 44* 199 ± 45* 195 ± 47* 191 ± 53
53.2 (3.9, 169)* 52.9 (1, 158)* 98.3 (4, 400)* 196 (23.5, 1632)
1.66 (0.2, 16.2)* 2.0 (0.2, 119.1)* 2.6 (0.2, 63.3)* 3.5(0.2, 187)
391 ± 12* 949 ± 21* 739 ± 10* 780 ± 61
9 (9.4%) 43 (22.1%) 87 (22.4%) 78 (23.6%)
11 (11.2%) 82 (42.3%) 226 (58.2%) 219 (66.3%)
rulonephritis; ADPKD; autosomal dominant.
DRD, Modification of Diet in Renal Disease; EPI, CKD epidemiology.
id hormone; hs-CRP, high-sensitivity C-reactive protein;
vs. stage V.
Table 2 eGFR thresholds associated with metabolic complications with a sensitivity of 90%
Complications eGFR, mL/min/1.73 m2 Specificity eGFR, mL/min/1.73 m2 Specificity
(Abbreviated MDRD) % (CKD-EPI) %
Hyperphosphatemia 55.3 28 86.3 64
Hyperparathyroidism 35.8 50 39.9 53
Anemia 40.5 58 44.2 64
Hyperuricemia 39.1 35 45.6 33
Hyperkalemia 41 31 40.1 36
Hypoalbuminemia 32.9 45 35.4 45
Acidosis 29.8 59 27.8 59
Microinflammation 43.3 26 57.8 21
eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
Figure 1 Prevalence of metabolic complications according to
stages of chronic kidney disease.
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ate analyses followed by multivariate Cox proportional
hazard regression analysis. Receiver operating characteris-
tic (ROC) analysis was used to determine the optimal cut-
off number of complications for outcome prediction. The
presence of more than 3 metabolic complications discrimi-
nated between patients with and without renal progression
(sensitivity, 81% and specificity, 67%) and death (sensitivity,
76% and specificity, 61%). The power of the contribution
of each variable to the model fit was estimated by deter-
mining the percent reduction of the pseudo-R2 value
resulting from the sequential omission of the maximum
likelihood-ratio of each variable from the complete model
[13]. The assumption of proportionality was checked
graphically using complementary log-log plots and was
found to be acceptable for the risk factors of interest. All
statistical tests were 2-tailed, and a p-value less than 0.05
was considered statistically significant. Data were analyzed
using the SPSS 17.0 software for Windows XP (SPSS Inc.,
Chicago, IL).
Results
The mean age of the study patients was 66.8 ± 13 years,
and 640 (55.3%) patients were men. The mean eGFR was
32.0 ± 26.3 mL/min/1.73 m2. Diabetes mellitus (DM) was
the leading cause of renal disease (43.5%). Table 1 summa-
rizes the baseline characteristics of the study population.
Of the 1157 patients who were enrolled in the study, 1068
(92.3%) patients presented with at least one metabolic
complication. The eGFR thresholds determined by ROC
analysis with a sensitivity of 90% for any metabolic compli-
cation were 60.8 and 74.3 mL/min/1.73 m2, using MDRD
and CKD Epidemiology Collaboration equations, respect-
ively (Table 2). Figure 1 summarizes the prevalence of
metabolic complications according to the stages of CKD.
After a mean follow-up of 24.5 ± 12.5 months (2368.6
patient-years), 283 (24.5%) patients (11.9 per 100 patient-
years) had renal progression and 118 (10.2%) patients
(4.9 per 100 patient-years) had died. Causes of deathincluded cardiovascular diseases (28 patients), infection
(50 patients), gastrointestinal bleeding (4 patients), malig-
nancies (3 patients), respiratory disorders (2 patients), hep-
atic diseases (2 patients), and other diseases (29 patients).
The incidences of renal progression and death were 1.8
and 2.0 per 100 patient-years, respectively, for patients
with eGFR ≥ 45 mL/min/1.73 m2; and 14.7 and 5.8 per
100 patient-years, respectively, for patients with eGFR
below 45 mL/min/1.73 m2.
Table 3 lists the univariate hazard ratios for renal pro-
gression and all-cause mortality according to the eGFR
levels. In patients with eGFR < 45 mL/min/1.73 m2,
number of metabolic complications (more than 3, HR:
2.18; 95% CI: 1.48–3.22; p < 0.001) was an independent
risk factor for renal progression after adjustment for pa-
tient demographic characteristics (age, gender, DM and
CKD stage, model 1, Table 4). Independent associations
and the hierarchical analyses of diverse metabolic com-
plications with renal progression are reported in model
2 of Table 4. These factors included hyperphosphatemia
(HR: 2.09; 95% CI: 1.57–2.80; p < 0.001), anemia (HR: 2.64;
Table 3 Univariate hazard ratios for renal progression and all-cause mortality according to eGFR levels









Variable HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age 1.04 (0.93 - 1.09) 0.18 0.98 (0.97 - 0.99) <0.001 1.13 (1.05 - 1.22) 0.002 1.06 (1.04 - 1.08) <0.001
Male gender 1.05 (0.28 - 3.93) 0.948 0.75 (0.59 - 0.94) 0.015 0.57 (0.16 - 2.02) 0.38 0.75 (0.52 - 1.09) 0.139
Diabetes (yes vs. no) 4.89 (1.22 - 9.61) 0.025 1.88 (1.47 - 2.42) <0.001 1.08 (0.28 - 4.18) 0.91 1.36 (0.93 - 1.99) 0.118
Hypertension (yes vs. no) 3.34 (0.62 - 18.14) 0.274 1.34 (0.87 - 2.08) 0.189 3.41 (0.10 - 11.34) 0.234 0.82 (0.46 - 1.47) 0.503
Hypercholesterolemia (yes vs. no) 0.61 (0.16 - 2.29) 0.464 1.06 (0.83 - 1.35) 0.641 0.55 (0.15 - 1.97) 0.361 0.79 (0.55 - 1.16) 0.234
Smoking (yes vs. no) 6.15 (1.27 - 9.82) 0.024 0.95 (0.74 - 1.22) 0.679 2.67 (0.75 - 9.51) 0.13 0.95 (0.64 - 1.41) 0.789
Obesity (yes vs. no) 0.89 (0.11 - 6.98) 0.858 1.17 (0.84 - 1.62) 0.354 1.46 (0.31 - 6.87) 0.635 0.65 (0.34 - 1.25) 0.195
Hyperphosphatemia (yes vs. no) 0.13 (0.02 - 1.06) 0.057 4.27 (3.29 - 5.53) <0.001 0.31 (0.07 - 1.49) 0.143 1.39 (0.95 - 2.05) 0.088
Hyperparathyroidism (yes vs. no) 0.69 (0.08 - 5.58) 0.725 2.69 (2.31 - 3.57) <0.001 2.12 (0.27 - 16.75) 0.477 2.01 (1.32 - 3.04) 0.001
Anemia (yes vs. no) 1.15 (0.37 - 6.22) 0.567 11.9 (5.33 - 26.8) <0.001 2.22 (0.62 - 7.71) 0.225 2.63 (1.37 - 5.05) 0.004
Hyperuricemia (yes vs. no) 0.04 (0.01 - 1.82) 0.563 0.87 (0.67 - 1.11) 0.266 2.45 (0.52 - 11.55) 0.258 1.99 (1.37 - 2.92) <0.001
Hyperkalemia (yes vs. no) 3.78 (0.47 - 30.7) 0.214 1.69 (1.31 - 2.19) <0.001 3.16 (0.39 - 25.05) 0.276 1.11 (0.71 - 1.74) 0.649
Hypoalbuminemia (yes vs. no) 5.02 (1.01 - 7.42) 0.004 4.02 (3.16 - 5.12) <0.001 4.79 (1.38 - 6.51) 0.013 3.56 (2.43 - 5.22) <0.001
Acidosis (yes vs. no) 0.49 (0.01 - 1.01) 0.756 3.35 (2.64 - 4.26) <0.001 5.18 (0.64 - 42.12) 0.124 1.72 (1.17 - 2.53) 0.006
Microinflammation (yes vs. no) 2.43 (0.49 - 12.1) 0.276 1.33 (1.03 - 1.71) 0.03 4.82 (1.36 - 7.10) 0.015 1.35 (0.89 - 2.03) 0.148
CVD (yes vs. no) 2.81 (2.61 - 18.2) 0.004 4.56 (2.25 - 9.27) <0.001 0.05 (0.01 - 20.33) 0.695 2.22 (1.35 - 3.64) 0.002
Metabolic complications (≥3 vs. <3) 1.54 (0.19 - 12.5) 0.688 5.62 (3.80 - 8.32) <0.001 1.25 (0.16 - 9.48) 0.835 4.35 (2.47 - 7.63) <0.001
HR, hazard ratios; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease.
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95% CI: 2.04–3.57; p < 0.001) and microinflammation (HR:
1.36; 95% CI: 1.02–1.80; p = 0.038, Table 4). For patients
with eGFR ≥ 45 mL/min per 1.73 m2, only hypo-
albuminemia (HR: 3.25; 95% CI: 1.73–4.61; p <0.001) was
independently associated with renal progression (Table 4).
The presence of ≥3 metabolic complications (HR:
3.71; 95% CI: 2.35–5.87; p < 0.001, model 1), hyper-
uricemia (HR: 2.09; 95% CI: 1.39–3.13; p < 0.001) and
hypoalbuminemia (HR: 2.39; 95% CI: 1.54–3.69; p < 0.001,
model 2) independently predicted death in patients
with eGFR < 45 mL/min/1.73 m2 (Table 5). Hypo-
albuminemia (HR: 5.87; 95% CI: 1.22–8.21; p = 0.001)
and microinflammation (HR: 3.31; 95% CI: 1.61–7.82;
p = 0.027) independently predicted death in patients
with higher eGFR (Table 5). The presence of ≥3 metabolic
complications and hypoalbuminemia had the greatest con-
tribution to the prediction of both renal progression and
death in patients with eGFR < 45mL/min/1.73 m2, as deter-
mined by percent reduction of pseudo- R2 values. Figure 2
shows the cumulative renal survival and overall survival
according to eGFRs and the presence of hypoalbuminemia.
Cumulative renal survival and overall survival, according
to the number of complications and hypoalbuminemia in
patients with eGFR < 45 mL/min/1.73 m2 are illustrated
in Figure 3.Discussion
The KDIGO Controversies Conference on the definition
and classification of CKD proposed the subdivision of
stage 3 of the KDOQI classification into two stages
(above and below 45 ml/min per 1.73 m2) due to the
steep rise in risks (all-cause and cardiovascular mortality,
kidney failure, acute kidney injury and progressive CKD)
associated with lower eGFR [9]. In the present prospect-
ive study we evaluated the associations of different types
and numbers of CKD-related metabolic complications
with renal progression and all-cause mortality in patients
with eGFRs above and below 45 mL/min/1.73 m2. We
found that hypoalbuminemia was a unique and common
predictor of renal progression and death in both groups
of patients, independent of the patients’ demographic
characteristics, traditional risk factors, severity of renal
dysfunction and other metabolic abnormalities. The
number of metabolic complications (≥ 3) was an inde-
pendent factor associated with renal progression and
death in patients with eGFR < 45 mL/min/1.73 m2.
Most CKD-related metabolic complications were associ-
ated with renal progression and death in patients with
eGFR < 45 mL/min/1.73 m2 rather than in those patients
with higher eGFR. Metabolic complications associated
with renal progression in patients with eGFR < 45 mL/min
were hyperphosphatemia, anemia, microinflammation and
Table 4 Multivariate Cox regression analysis of renal progression with the estimated contribution of each covariates to
the prediction
HR p R2 reduction
(95% CI) (%)
eGFR ≥ 45 ml/min/1.73 m2
Diabetes (yes vs. no) 1.91 (1.18 - 2.11) 0.035 1.11
Hypoalbuminemia (yes vs. no) 3.25 (1.73 - 4.61) <0.001 6.91
CVD (yes vs. no) 2.81 (2.61 - 4.82) 0.004 2.39
eGFR < 45 ml/min/1.73 m2
Model 1
Age 0.98 (0.97 - 0.99) <0.001 0.70
Gender (male vs. female) 0.93 (0.74 - 1.18) 0.059 0.10
Diabetes (yes vs. no) 1.71 (1.42 - 2.34) <0.001 1.29
CKD stage 2.67 (2.19 - 3.26) <0.001 7.67
Metabolic complications (≥3 vs. <3) 2.18 (1.48 - 3.22) <0.001 0.51
Model 2
Age 0.98 (0.97 - 0.99) <0.001 0.74
Gender (male vs. female) 1.05 (0.81 - 1.37) 0.704 <0.001
CKD stage 2.30 (1.87 - 2.83) <0.001 5.68
CVD (yes vs. no) 3.29 (1.56 - 6.99) 0.002 0.29
Hyperphosphatemia (yes vs. no) 2.09 (1.57 - 2.80) <0.001 1.26
Hyperparathyroidism (yes vs. no) 0.92 (0.64- 1.31) 0.633 <0.001
Anemia (yes vs. no) 2.64 (1.38 - 5.01) 0.003 0.41
Hyperuricemia (yes vs. no) 1.03 (0.78 - 1.35) 0.857 <0.001
Hypoalbuminemia (yes vs. no) 2.58 (2.04 - 3.57) <0.001 4.54
Acidosis (yes vs. no) 1.24 (0.93 - 1.67) 0.15 <0.001
Microinflammation (yes vs. no) 1.36 (1.02 - 1.80) 0.038 0.15
HR, hazard ratios; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease.
Model 1: adjusted for patient demographic characteristics, CKD stage and number of complications.
Model 2: hierarchical analyses of diverse metabolic complications adjusted for age, gender and CKD stage.
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http://www.biomedcentral.com/1471-2369/14/92hypoalbuminemia. Those associated with death were
hypoalbuminemia and hyperuricemia. Whereas, in pa-
tients with eGFR ≥ 45 mL/min1.73 m2, hypoalbuminemia
predicted renal progression, and hypoalbuminemia and
microinflammation predicted death. Prospective studies
evaluating the associations of all CKD-related metabolic
complications with outcomes in patients with eGFRs
above and below 45 mL/min/1.73 m2 have been rarely
reported. Our findings may offer novel insight into the
associations between metabolic complications and pa-
tient outcomes based on the stage of CKD.
Hypoalbuminemia is the main feature of the
malnutrition-inflammation-atherosclerosis complex and it
is probably associated with CKD as well as many other
conditions. However, the significant association between
hypoalbuminemia and patient outcomes noted in this
study despite adjustments for all these conditions again
highlights the importance of this risk factor in patient
prognosis (models 1 and 2 of Tables 4 and 5). Sarcopeniaand a lower BMI were also considered as possible causes
of hypoalbuminemia. In the current study, the preva-
lence rates of sarcopenia, which manifests itself clinic-
ally in the presence of fractures (defined by an ICD-9
coding of 8000-8290), and underweight status (defined
according to the WHO classification, as a BMI <18 kg/m2)
were 2.2% and 2.1%, respectively. The contribution of
sarcopenia and underweight status as possible intermedi-
ates or confounders of hypoalbuminemia may be small be-
cause of the low prevalence of these 2 conditions in our
study population.
The strong independent association of hypoalbuminemia
with renal progression and death in CKD patients, stronger
than all other CKD-related metabolic complications, is im-
portant clinically. Findings from the Atherosclerosis Risk
in Community Study revealed that serum albumin levels
were inversely correlated with the risk of decline of renal
function, suggesting a unique role for hypoalbuminemia
as an antecedent pathway for CKD [8]. Like previous
Table 5 Multivariate Cox regression analysis of all-cause mortality with estimated contribution of each covariate to the
prediction
HR p R2 reduction
(95% CI) (%)
eGFR ≥ 45 ml/min/1.73 m2
Age 1.11 (1.03 - 1.19) 0.006 16.13
Hypoalbuminemia (yes vs. no) 5.87 (1.22- 8.21) 0.001 5.61
Microinflammation (yes vs. no) 3.31 (1.61 - 7.82) 0.027 4.45
eGFR < 45 ml/min/1.73 m2
Model 1
Age 1.06 (1.04 - 1.08) <0.001 3.70
Gender (male vs. female) 0.84 (0.59 - 1.21) 0.36 <0.001
Diabetes (yes vs. no) 1.36 (094–1.97) 0.126 <0.001
CKD stage 1.13 (0.91 - 1.41) 0.279 <0.001
Metabolic complications (≥3 vs. <3) 3.71 (2.35 - 5.87) <0.001 2.60
Model 2
Age 1.07 (1.47 - 1.09) <0.001 5.00
Gender (male vs. female) 0.66 (0.45 - 0.10) 0.061 0.14
CKD stage 1.37 (1.07 - 1.75) 0.012 0.68
CVD (yes vs. no) 1.86 (1.09 - 3.19) 0.024 0.39
Hyperphosphatemia (yes vs. no) 0.98 (6.23 - 1.55) 0.939 <0.001
Hyperparathyroidism (yes vs. no) 1.36 (0.97 - 2.42) 0.223 <0.001
Anemia (yes vs. no) 1.10 (0.61 - 2.00) 0.924 <0.001
Hyperuricemia (yes vs. no) 2.09 (1.39 - 3.13) <0.001 1.37
Hypoalbuminemia (yes vs. no) 2.39 (1.54 - 3.69) <0.001 2.11
Acidosis (yes vs. no) 1.37 (0.87 - 2.17) 0.173 <0.001
Microinflammation (yes vs. no) 1.46 (0.95 - 2.24) 0.083 <0.001
HR, hazard ratios; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease.
Model 1: adjusted for patient demographic characteristics, CKD stage and number of complications.
Model 2: hierarchical analyses of diverse metabolic complications adjusted for age, gender and CKD stage.
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http://www.biomedcentral.com/1471-2369/14/92investigations, our study revealed a significant association
between low serum albumin levels and mortality, inde-
pendent of inflammation markers, such as C-reactive pro-
tein [14]. The NKF/DOQI guidelines suggested monthly
measurements of serum albumin levels in maintenance
dialysis patients [15]. However, despite abundant evidence,
clinical guidelines are required to standardize the timing
for screening serum albumin in predialysis CKD patients.
Further, large-scale studies are needed to investigate the
clinical improvement of patients who have had their
hypoalbuminemia corrected.
The reasons for the apparent insignificance of metabolic
complications in predicting outcomes, despite the high
prevalence of certain complications (e.g., hyperphos-
phatemia and anemia) in patients with eGFR ≥ 45 mL/
min/1.73 m2 should be investigated. One possible explan-
ation is that metabolic complications may reflect both
the endocrine and excretory functions of the kidneys and
may not be sufficient to cause organ dysregulation. Thepresence of comorbidities and harmful systemic condi-
tions may be more significant than the subtle dysfunction
of a simple organ. These divergent findings clearly indi-
cate the heterogeneous clinical course and dissimilar bio-
logical behaviors of patients with eGFR below or above
45 mL/min/1.73 m2. Further, these findings provide evi-
dence that will help refine risk stratification and to estab-
lish the effective allocation of medical resources in an
effort to alleviate the significant burden of CKD. In patients
whose eGFRs are above 45 mL/min/1.73 m2, more atten-
tion should be paid to the treatment of comorbidities ra-
ther than CKD-related complications, while, vigorous
treatment of CKD-related complications should be empha-
sized for late-stage patients.
In the present study, most of the cutoff points chosen to
define metabolic complications were based on current
guidelines. However, comparison of our findings with those
from others groups may be difficult because the thresholds
may have changed due to variations in guidelines over time
Figure 2 Cumulative renal survival (A) and overall survival
(B) based on hypoalbuminemia in patients with eGFR above or
below 45 mL/min per 1.73 m2 (log-rank test, p < 0.001).
Figure 3 Cumulative renal (A) and overall survival (B) based on
hypoalbuminemia and presence of more than 3 metabolic
complications in patients with eGFR below 45 mL/min per 1.73 m2
(log-rank test, p < 0.001).
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http://www.biomedcentral.com/1471-2369/14/92and the different definitions of renal progression used in
studies [16,17]. Notably, the time of onset of CKD-related
complications in our patients was quite different from that
reported in other studies [16-18]. For example, the eGFR
threshold for the development of hyperphosphatemia in
our patients was approximately 10 mL/min per 1.73 m2
higher than that in Caucasian patients [17]. The unadjusted
prevalence rates of hyperphosphatemia were approximately
5.5-fold and 3-fold higher in our stages 1-3 and stages 4
and 5 patients, respectively, than the prevalence rates of
hyperphosphatemia in participants from the same eGFR
strata in the National Health and Nutrition ExaminationSurvey [18]. Genetic backgrounds can influence the clinical
features and outcomes in CKD patients of different ethnic
origins [19]. For example, Africans are more likely to de-
velop anemia, hyperphosphatemia and hyperuricemia and
have a higher eGFR threshold for its development than
Caucasians [20], while Oriental Asian patients generally ex-
perience more metabolic complications such as anemia,
hypocalcemia, and hyperparathyroidism than Caucasians
at all eGFRs levels [16]. The exact reason for these discrep-
ancies in the development thresholds for these different co-
horts is unclear. However, differences among the study
populations, comorbidities, dietary habits, ethnicity-related
PTH resistances, vitamin D metabolism, fibroblast growth
factor-23 levels, education perceptions and compliance
may partly influence this phenomenon. Paradoxically,
Asian patients have greater survival advantages, despite
these metabolic abnormalities [21]. In this study, we found
that the most metabolic abnormalities are more likely to
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http://www.biomedcentral.com/1471-2369/14/92be associated with adverse outcomes only in patients with
eGFR < 45 ml/min per 1.73 m2. Further large-scale clinical
trials should be conducted to clarify the significance of
metabolic complications on clinical outcomes in Asian
CKD patients.
The strengths of our study include the study design,
which was a large prospective cohort of patients with di-
verse renal functions, the collection of complete measure-
ments of common traditional risk factors and CKD-related
metabolic complications, and follow-up using a standard-
ized program, which limited the number of noncompliant
participants and facilitated the accurate recording of pa-
tients’ renal functions and outcomes. In the clinical setting,
the use of a composite of a decline in eGFR by > 50% and
the presence of ESRD requiring dialysis, to define renal
progression, may have facilitated the timely detection of
changes in renal function in patients with early-stage CKD.
However, there were several limitations to this analysis, in-
cluding the interrogation of a homogeneous Asian popula-
tion from a single center and the lack of analysis of the
time-dependent variations. The findings of the present
study should not be interpreted in causal terms. The ana-
lysis of time-dependent variations in individual complica-
tions has been extensively described in other studies
[22-25]. Reference to baseline complications in the assess-
ment of patient outcomes may provide useful information
to help clinicians make prognoses and to facilitate
decision-making regarding CKD complications and out-
comes when it is initially detected. We applied the most
commonly used methods to estimate eGFR (i.e., the
MDRD and CKD-Epidemiology Collaboration equations)
rather than the gold-standard method (iothalamate GFR).
The later method does not appear to be superior to
equation-based estimations of eGFR in the explanation of
CKD-related complications, except anemia [26].
Conclusions
In this prospective study, we have demonstrated that
hypoalbuminemia is a unique and strong predictor of
renal progression and all-cause mortality in CKD pa-
tients, independent of demographic characteristics, trad-
itional risk factors, severity of renal dysfunction, the
present of cardiovascular disease, and other metabolic
abnormalities. Most of other metabolic complications
and the number of complications (more than 3) were as-
sociated with the clinical outcomes of patients who had
eGFR < 45 mL/min/1.73 m2 rather than in those with
higher eGFRs. The findings from this study offer a novel
insight into the association between metabolic complica-
tions and clinical outcomes, and may help to refine risk
stratification based on the stage of CKD.
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